###begin article-title 0
Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation
###end article-title 0
###begin p 1
Recommended by Carlos Esquivel
###end p 1
###begin p 2
###xml 687 695 <span type="species:ncbi:9606">patients</span>
###xml 748 756 <span type="species:ncbi:9606">patients</span>
###xml 797 805 <span type="species:ncbi:9606">patients</span>
###xml 826 834 <span type="species:ncbi:9606">patients</span>
###xml 1114 1121 <span type="species:ncbi:9606">patient</span>
It has been shown that certain chemokine receptor polymorphisms may correspond to certain complications after organ transplantation. Ischemic-type biliary lesion (ITBL) encounters for major morbidity and mortality in liver transplant recipients. So far, the exact cause for ITBL remains unclear. Certain risk factors for the development of ITBL like donor age and cold ischemic time are well described. In a previous study, a 32-nucleotide deletion of the chemokine receptor-5Delta32 (CCR-5Delta32) was strongly associated with the incidence of ITBL in adult liver transplantation. This study re-evaluates the association of CCR-5Delta32 gene polymorphism and the incidence of ITBL. 169 patients were included into this retrospective analysis. 134 patients were homozygous for wild-type CCR-5, 33 patients heterozygous, and 2 patients were homozygous for CCR-5Delta32 mutation. There were no major differences in donor or recipients demographics. No association was found between CCR-5Delta32 mutation and the development of ITBL. We conclude that CCR-5Delta32 is no risk factor for the development of ITBL in our patient cohort.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 247 255 247 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 388 395 <span type="species:ncbi:9606">Patient</span>
The terms "nonanastomotic biliary strictures", "intrahepatic biliary strictures", or "ischemic-type biliary lesion" (ITBL) are often used as synonyms for hilar or intrahepatic diffuse bile duct strictures, necrosis, ecstasies, or dilatations (see Figure 1) [1, 2]. The reported incidence of ITBL after OLT varies between 1.4% and 20% [3-5]. Some centers report even higher incidence [6]. Patient and graft survival after the diagnosis of ITBL are significantly reduced [7]. ITBL is the third most common reason for hepatic retransplantation [8]. This complication encounters for major morbidity and mortality, creates high costs, and aggravates organ shortage [7, 8].
###end p 4
###begin p 5
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 530 531 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 662 663 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 759 761 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 903 905 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1105 1107 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1208 1210 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1220 1222 1200 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1256 1258 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 886 891 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1039 1047 <span type="species:ncbi:9606">patients</span>
The exact cause of ITBL still remains unclear. Only relevant risk factors are described. However, data about risk factors for the development of ITBL are inconsistent. A recent study on 1113 liver transplant patients showed no relevant donor or recipient risk factor of ITBL [5]. There are only two studies evaluating the impact of chemokine receptors (CCR) on the development of ITBL [6, 9]. In Moench's study on 146 OLT patients CCR-5Delta32 mutation was evaluated and correlated with a significant increased incidence of ITBL [6]. A recent study on 137 pediatric liver transplants failed to show an association between CCR-5Delta32 and biliary complications [9]. CCR-5Delta32 is a single base-pair deletion of CCR-5 that leads to a nonfunctional receptor [10]. The clinical impact of this mutation was first described for homozygous CCR-5Delta32 Caucasians being highly resistant to HIV-1 infection [11]. If there was an immunological cause for ITBL, a nonfunctional CCR might be relevant for this complication. Homozygous CCR-5Delta32 patients showed a significant increased renal allograft survival [12]. Experimental studies correlated a nonfunctional CCR-5 with less acute rejection episodes in lung [13], heart [14] and islet cell transplantation [15].
###end p 5
###begin p 6
###xml 122 130 <span type="species:ncbi:9606">patients</span>
The aim of this study was to re-examine a correlation of CCR-5Delta32 genotype with the susceptibility of ITBL within our patients.
###end p 6
###begin title 7
###xml 3 11 <span type="species:ncbi:9606">Patients</span>
2. Patients and Methods
###end title 7
###begin p 8
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
###xml 722 727 <span type="species:ncbi:9606">Child</span>
###xml 854 857 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1013 1021 <span type="species:ncbi:9606">patients</span>
###xml 1051 1059 <span type="species:ncbi:9606">patients</span>
###xml 1249 1257 <span type="species:ncbi:9606">patients</span>
169 liver transplant patients were analyzed retrospectively. All patients were transplanted at the transplant center of the Humboldt University of Berlin between 03/2002 and 03/2005 and were included during routine Follow-up examination. Follow-up period was 24 months minimum. 11 patients with the established diagnosis of ITBL, that were transplanted earlier than 03/2001, were selectively included into this study due to the low incidence of ITBL of only 4.0% within our patients. The diagnosis of ITBL was made within the first year after transplantation in 82% of the patients. The following demographic data were extracted from the hospital records and evaluated: age, gender, underlying liver disease, blood group, Child-Pugh score (CPS), model for end stage liver disease score (MELD score), initial immunosuppression, cytomegalovirus infection (CMV), HLA match, donor age and gender, donor serum sodium, cause of brain death and length of stay on intensive care unit (ICU) prior to organ harvesting. 154 patients received a cadaver graft, 15 patients received a graft from a living donor. Altogether, 19 split-liver transplantation were included. The local ethic committee approved the study. Written informed consent was obtained from all patients before blood was taken for DNA analysis.
###end p 8
###begin title 9
3. Definition of ITBL
###end title 9
###begin p 10
ITBL was defined as nonanastomotic intra- or extrahepatic biliary strictures without any history of hepatic artery complications, ABO, incompatibility or other known causes of bile duct damages. In all cases patency of the hepatic artery was proved by Doppler ultrasound, computer tomography based angiography or conventional angiography. Recurrence of primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) and vanishing bile duct syndrome were ruled out in all cases by liver biopsy. Diagnosis of ITBL was always established with endoscopic retrograde cholangiography or percutaneous transhepatic cholangiography.
###end p 10
###begin title 11
4. Genotype Analysis
###end title 11
###begin p 12
###xml 193 195 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 277 279 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 485 487 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 555 557 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 612 614 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 655 657 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 750 752 744 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
All genotype analyses were performed at the Johannes Gutenberg University of Mainz, Department of Transplantation Surgery. For analysis of the CCR-5 genotype, genomic DNA was prepared from 200 muL peripheral blood using the QIAamp DNA blood kit (Qiagen, Cologne, Germany). 2.5 muL of DNA were amplified by PCR using the following CCR-5 specific primers: CCR-sense, 5'-CAAAAAGAAGGTCTTCATTACACC-3' and CCR-5-antisense, 5'-CCTGTGCCTCTTCTTCTCATTTCG-3'. The PCR mixture was composed of 2.5 muL 10 x PCR buffer (Roche Molecular Systems, Mannheim, Germany), 0.5 muL of 12.5 mmol/L dNTP (PeqLab, Erlangen, Germany), 2.5 muL of each sense and antisense primer (10 mumol/L), and 1.25 U AmpliTag DNA polymerase (Roche Molecular Systems) in a total volume of 25 muL. Forty PCR cycles were run on a Genius thermocycler (Techne, Cambridge, UK), using the following temperature profile: initial denaturation, 94degreesC 3 minutes; amplification, 94degreesC 1 minute, 64degreesC 1 minute, and, 72degreesC 1 minute (40 cycles); terminal elongation, 72degreesC 9 minutes. The size of the wild-type product was 189 base pairs (bp), and the CCR-5Delta32 allele yielded a product of 157 bp. PCR products were analyzed by 2% agarose gel electrophoresis.
###end p 12
###begin title 13
5. Statistical Analysis
###end title 13
###begin p 14
All statistical calculations were performed in SPSS 11.3 (SPSS Inc., Chicago, USA). Data are given as mean values +/- standard deviation. Descriptive statistics were used to summarize the donor and recipients characteristics. For independent variables, cross tabulations and chi-square tests were performed. Nonparametric variables were evaluated with Fisher's exact test, and asymptotic significance was calculated.
###end p 14
###begin p 15
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
All of the tests performed were two-sided. P-values of P < .05 were considered as statistically significant. All calculations were performed in association with the Department of Biometrical Medicine of the Humboldt University of Berlin.
###end p 15
###begin title 16
6. Results
###end title 16
###begin title 17
###xml 5 12 <span type="species:ncbi:9606">Patient</span>
6.1. Patient Characteristics and Genotype Distribution
###end title 17
###begin p 18
###xml 533 540 513 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 230 238 <span type="species:ncbi:9606">Patients</span>
A total number of 169 liver transplant recipients were available for genotyping and complete data analysis. Gender and age were equally distributed between wild-type group (wt/wt) and heterozygous CCR-5Delta32 group (wt/Delta32). Patients in the homozygous group (Delta32/Delta32) were female and male. The observed genotype frequency was as expected assessed by Hardy-Weinberg equilibrium in the study population. There were no differences between wt/wt group and wt/Delta32 group regarding to CPS score, MELD score or blood group (Table 1).
###end p 18
###begin p 19
###xml 133 141 <span type="species:ncbi:9606">patients</span>
There were no statistical significant differences in the composition of underlying liver disease of group wt/wt and wt/Delta32. Both patients with Delta32/Delta32 had primary biliary cirrhosis as underlying liver disease.
###end p 19
###begin p 20
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 252 255 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
Initial immunosuppression was tacrolimus based in 82.6% in the wt/wt group compared to 84.8% in the wt/Delta32 group. Likewise, cold ischemic time and HLA match showed no differences between groups. Both homozygous Delta32 patients had zero HLA match. CMV infection that demanded ganciclovir treatment was present in approximately 30% in the wt/wt and wt/Delta32 group and in both homozygous patients.
###end p 20
###begin title 21
6.2. Donor Characteristics
###end title 21
###begin p 22
###xml 420 427 400 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
There were no differences between group regarding donor age or gender. Donors of group Delta32/Delta32 were younger (35.7 years versus 46.5 years and 48.5 years). Mean donor serum sodium was 146.9 mmol/L in the wt/wt group compared with 147.7 mmol/L in the wt/Delta32 group and 155.5 mmol/L in the Delta32/Delta32 group. Data of causes of brain death and length of stay on the ICU prior to organ harvesting are shown in Table 2.
###end p 22
###begin title 23
6.3. Incidence ITBL and Rate of Retransplantation
###end title 23
###begin p 24
###xml 366 373 358 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 414 421 <span type="species:ncbi:9606">patient</span>
Incidence of ITBL was 11.2% in this study due to the selection of patients with ITBL that were additionally included into this evaluation. Homozygous Delta32 patients developed no ITBL compared to 11.2% and 12.1% of homozygous wild-type patients and heterozygous patients, respectively. The rate of retransplantation was 3.0% in both wt/wt and wt/Delta32 group (see Table 3). Retransplantation of the heterozygous patient was indicated due to chronic ductopenic rejection following OLT for PSC. In the wt/wt group, the indications for retransplantation were INF, cryptogenic recirrhosis, and ITBL.
###end p 24
###begin title 25
7. Discussion
###end title 25
###begin p 26
The problem of genetic association studies and complex clinical syndromes or diseases must be addressed. One can always question the usefulness of these studies that are often even small in sample size. Most of these studies are statistically underpowered. On the other side, it seems important to undertake replication studies for reported associations between genetic polymorphisms and diseases, especially in diseases of major clinical importance.
###end p 26
###begin p 27
###xml 186 188 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 190 192 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 296 298 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
In this study, the distribution of heterozygous Delta32 and homozygous Delta32 mutation was very consistent with the published data of the global distribution of this gene polymorphism [10, 16]. Heterozygous and homozygous genotypes occur in Caucasian population in 15%-20% and 1%, respectively [16]. Heterozygous individuals show no abnormal receptor function compared with wt/wt individuals. All examined donor and recipient factors showed no statistical differences between groups. This seems important due to the small number of patients included in this study and the possible bias by including selected patients with the diagnosis of ITBL into the study cohort.
###end p 27
###begin p 28
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1061 1062 1045 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1831 1832 1803 1804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1980 1981 1952 1953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1982 1983 1954 1955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
###xml 910 918 <span type="species:ncbi:9606">patients</span>
###xml 959 967 <span type="species:ncbi:9606">patients</span>
###xml 1305 1313 <span type="species:ncbi:9606">patients</span>
###xml 1768 1776 <span type="species:ncbi:9606">patients</span>
###xml 2014 2022 <span type="species:ncbi:9606">patients</span>
###xml 2029 2037 <span type="species:ncbi:9606">patients</span>
###xml 2104 2112 <span type="species:ncbi:9606">patients</span>
###xml 2195 2203 <span type="species:ncbi:9606">patients</span>
###xml 2261 2268 <span type="species:ncbi:9606">patient</span>
###xml 2409 2417 <span type="species:ncbi:9606">patients</span>
###xml 2455 2463 <span type="species:ncbi:9606">patients</span>
###xml 2514 2522 <span type="species:ncbi:9606">patients</span>
Despite increasing success rates in clinical OLT over the past decades, ITBL remains a major cause for recipient morbidity and mortality [1-5]. This single complication creates enormous costs and aggravates organ shortage. Up till today, only risk factors for ITBL could be identified in various clinical studies. The length of cold ischemic time was correlated with the development of ITBL [1-4]. Donor age was found to be a significant risk factor for ITBL. Other studies were not able to show these correlations [5]. Immunological causes seem to play only a minor role in the pathogenesis of ITBL. Moench et al. described a single base-pair deletion in the coding region of the chemokine receptor-5Delta32, CCR-5Delta32, to be a significant risk factor for the development of ITBL. In Moench's study on 146 OLT patients CCR-5Delta32 was a significant risk factor for ITBL (incidence of ITBL in CCR-5Delta32 patients was 30% versus 11.7% in CCR-5 wild-type patients) and was correlated with a decreased survival rate after OLT. The overall ITBL rate was 15% [6]. The different incidence of ITBL of the study by Moench and this study may be a reason for the different findings, even though both investigators used the same definition of ITBL. Donors were younger in this study with 38.2 +/- 16 (non-ITBL patients) and 42.9 +/- 17 (ITBL) versus 46 +/- 14 (non-ITBL) and 52 +/- 14 (ITBL) in Moench's study. However, cold ischemic time was shorter in Moench's investigation (564 minutes (ITBL) and 538 minutes (non-ITBL) versus 637 minutes (ITBL) and 558 minutes (non-ITBL)). The use of arterial back table perfusion was also routinely done for all organs that were harvested by a team of our own. Fischer-Maas et al. analyzed CCR-5Delta32 polymorphism in 137 pediatric patients but showed no correlation with biliary complications [9]. The incidence of ITBL varies between 1.4% and 20% according to the literature, which might be a problem of different definition of this disease [3-5]. The rate of ITBL in our OLT patients (2100 patients between 1988 and 2004) is 4.0%. In the presented study on 169 OLT patients the overall incidence of ITBL was 11.7%, but only due to a selective inclusion of patients with the established diagnosis of ITBL. This practice of patient recruitment may be criticized, but we think it is justified according to our low incidence of ITBL. Thus, it was possible to investigate 19 patients with ITBL. ITBL rate in CCR-5Delta32 patients was virtually equal to the one in CCR-5 wild-type patients. No statistically significant differences regarding ITBL or retransplantation were observed.
###end p 28
###begin p 29
###xml 211 213 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 351 353 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 355 357 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 380 382 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 384 386 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 426 428 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 899 901 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 910 912 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 922 924 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 958 960 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1065 1067 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1221 1222 1193 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1224 1225 1196 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1227 1229 1199 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1368 1370 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1533 1535 1505 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1536 1538 1508 1510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1849 1851 1821 1823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1942 1944 1914 1916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1070 1078 <span type="species:ncbi:9606">Patients</span>
###xml 1951 1959 <span type="species:ncbi:9606">patients</span>
Why would CCR-5Delta32 mutation promote the development of ITBL? CCR-5Delta32 is a 32-base-pair deletion within the coding region of CCR-5, which results in a frame shift and generates a nonfunctional receptor [11]. Homozygous expression of CCR-5Delta32 is associated with a reduced risk of asthma and with a reduced severity of rheumatoid arthritis [17, 18], multiple sclerosis [19, 20], and primary biliary cirrhosis (PBC) [21]. In other words, the nonfunctional nature of CCR-5Delta32 protects the individual from autoimmune diseases where CCR-5 seems to play a central pathophysiological role. These data do not backup the theory, that immunological risk factors are dominant in the development of ITBL. Likewise, a correlation of a reduced survival rate with CCR-5Delta32 would not be consistent to the literature, where CCR-5Delta32 mutation is associated with an increased survival in renal [12], lung [13], heart [14] and islet cell transplantation [15]. In contrast to those findings, CCR-5Delta32 is strongly associated with an increased severity of PSC [22]. Patients suffering from PSC have been described as carrying a higher risk for ITBL, with a reported significantly increased incidence of 15.8% to 25% [1, 8, 23]. Another study reported PSC as the only independent risk factor for ITBL with an incidence of 31% compared with 9% of the control group [24]. However, the problem of differentiation between ITBL and recurrence of PSC must be addressed. Recurrence rates of 8.6% to 25% were described for PSC after OLT [25-27]. The diagnose of recurrence of PSC is based on cholangiographic findings of intrahepatic, hilar and/or exrahepatic strictures, duct irregularities and on the histopathological picture of fibrous cholangitis and/or fibro-obliterative lesions with or without ductopenia, biliary fibrosis, or biliary cirrhosis [28]. Most of these findings are neither pathognomonic for either recurrence of PSC nor ITBL [29]. All patients with ITBL in this study underwent percutaneous liver biopsy, and our pathologists ruled out PSC recurrence. There remains a diagnostic uncertainty.
###end p 29
###begin p 30
###xml 152 160 <span type="species:ncbi:9606">patients</span>
Since two of three studies failed to show an association between ITBL and CCR-5Delta32 gene polymorphism, a general recommendation for screening of OLT patients for CCR-5Delta32 does not seem to be justified.
###end p 30
###begin article-title 31
Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation
###end article-title 31
###begin article-title 32
Ischemic-type biliary complications after orthotopic liver transplantation
###end article-title 32
###begin article-title 33
Etiologic factors and incidence of ischemic type biliary lesions (ITBL) after liver transplantation
###end article-title 33
###begin article-title 34
Diffuse biliary tract injury after orthotopic liver transplantation
###end article-title 34
###begin article-title 35
Intrahepatic biliary strictures without hepatic artery thrombosis after liver transplantation: an analysis of 1,113 liver transplantations at a single center
###end article-title 35
###begin article-title 36
CC chemokine receptor 5Delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation
###end article-title 36
###begin article-title 37
Clinical outcome of ischemic-type biliary complications after liver transplantation
###end article-title 37
###begin article-title 38
Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation
###end article-title 38
###begin article-title 39
Analysis of the CC chemokine receptor 5Delta32 polymorphism in pediatric liver transplant recipients
###end article-title 39
###begin article-title 40
The case for selection at CCR5-Delta32
###end article-title 40
###begin article-title 41
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro
###end article-title 41
###begin article-title 42
CC chemokine receptor 5 and renal-transplant survival
###end article-title 42
###begin article-title 43
The role of the CC chemokine, RANTES, in acute lung allograft rejection
###end article-title 43
###begin article-title 44
Donor CCR5 Delta32 polymorphism and outcome following cardiac transplantation
###end article-title 44
###begin article-title 45
The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection
###end article-title 45
###begin article-title 46
Global distribution of the CCR5 gene 32-basepair deletion
###end article-title 46
###begin article-title 47
CC chemokine receptor 5 polymorphism in rheumatoid arthritis
###end article-title 47
###begin article-title 48
Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis
###end article-title 48
###begin article-title 49
Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis
###end article-title 49
###begin article-title 50
CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis
###end article-title 50
###begin article-title 51
Genetic factors in the pathogenesis of primary biliary cirrhosis
###end article-title 51
###begin article-title 52
CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis
###end article-title 52
###begin article-title 53
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center
###end article-title 53
###begin article-title 54
Biliary strictures after liver transplantation: clinical picture, correlates and outcomes
###end article-title 54
###begin article-title 55
Liver transplantation for sclerosing cholangitis
###end article-title 55
###begin article-title 56
Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease
###end article-title 56
###begin article-title 57
Recurrence of primary sclerosing cholangitis following liver transplantation
###end article-title 57
###begin article-title 58
Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?
###end article-title 58
###begin article-title 59
Intrahepatic cholestasis after liver transplantation
###end article-title 59
###begin p 60
###xml 155 162 <span type="species:ncbi:9606">patient</span>
Intrahepatic presentation of ischemic-type biliary lesion six months after hepatic transplantation for chronic hepatitis B-associated liver cirrhosis. The patient's hepatic artery is patent, and there is no other known cause for the destruction of the intrahepatic biliary tract.
###end p 60
###begin p 61
###xml 73 78 <span type="species:ncbi:9606">Child</span>
###xml 224 227 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 264 270 <span type="species:ncbi:10090">murine</span>
Recipient characteristics. MELD: model for end-stage liver disease; CPS: Child-Pugh score; BG: recipients blood group; wt/wt: wild-type CCR-5; wt/Delta32: heterozygous CCR-5Delta32; Delta32/Delta32: homozygous CCR-5Delta32; CMV: cytomegalovirus; OKT-3: monoclonal murine anti-CD-3 antibody.
###end p 61
###begin p 62
Donor characteristics. ICU: intensive care unit; wt/wt: wild-type CCR-5; wt/Delta32: heterozygous CCR-5Delta32; Delta32/Delta32: homozygous CCR-5Delta32.
###end p 62
###begin p 63
Events after transplantation. wt/wt: wild type CCR-5; wt/Delta32: heterozygous CCR-5Delta32; Delta32/Delta32: homozygous CCR-5Delta32; ITBL: ischemic-type biliary lesion; Re-OLT: retransplantation.
###end p 63

